Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | TACR2 | P21452 | 1/20 | 0.30 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6425959 | 0.98 | MEN1 (0.33) | MEN1KMT2ACHRM5HSD11B1PDE2A | |
| SCHEMBL6456664 | 0.93 | PDE2A (0.35) | PDE2AAKR1C3AKR1C2TACR2TACR3 | |
| SCHEMBL6425575 | 0.93 | AKR1C3 (0.39) | MEN1KMT2AAKR1C3AKR1C2 | |
| SCHEMBL6453546 | 0.91 | PDE2A (0.35) | PDE2AAKR1C3AKR1C2TACR2TACR3 | |
| SCHEMBL6423663 | 0.91 | HSD11B1 (0.34) | HSD11B1PGR | |
| SCHEMBL6424291 | 0.91 | AKR1C3 (0.39) | MEN1KMT2AAKR1C3AKR1C2 | |
| SCHEMBL6424758 | 0.90 | ALDH1A1 (0.37) | MEN1KMT2AHSD11B1 | |
| SCHEMBL6425052 | 0.89 | USP2 (0.36) | MEN1KMT2AHSD11B1AKR1C3AKR1C2 | |
| SCHEMBL6424162 | 0.89 | TSHR (0.35) | HSD11B1TAS1R3TAS1R2PGR | |
| SCHEMBL6424325 | 0.89 | MEN1 (0.33) | MEN1KMT2ACHRM5HSD11B1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | MEN1 3824/4885KMT2A 1519/4885CHRM5 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.